HSA published the Guidance on Therapeutic Product Registration in Singapore (April 2026) on 1 April 2026: eCTD format accepted for dossier submission with effect from 1 April 2026; CMC quality-defect declaration required from 1 June 2026. Singapore aligns with the ICH eCTD specification implemented by FDA, EMA, MHRA and TGA. Operational under the Health Products Act 2007.

The Health Sciences Authority published the updated Guidance on Therapeutic Product Registration in Singapore on 1 April 2026. The 171-page document, issued by HSA''s Health Products Regulation Group, refreshes the operational guidance under the Health Products Act 2007 (Act 14 of 2007) and Health Products (Therapeutic Products) Regulations 2016 (S 329/2016) for every applicant pursuing therapeutic product registration in Singapore.

Two operational changes anchor the April 2026 update. From 1 April 2026, the electronic Common Technical Document (eCTD) format is officially accepted for regulatory dossier submission, with applicants able to submit packages via the SG-HSA eCTD Portal using SG-HSA eCTD Specification version 1.1 — the official Singapore standard built on the ICH M2 Specification for the Electronic Common Technical Document (eCTD) v3.2.2 (16 July 2008). From 1 June 2026, applicants must additionally provide an official letter declaring no known quality defects in the Chemistry, Manufacturing and Controls (CMC) dossier at the point of submission.

The eCTD acceptance closes a long-standing harmonisation gap. The eCTD has been the international norm for pharmaceutical regulatory submission for over two decades. The European Medicines Agency mandated eCTD-only for the Centralised Procedure from 1 January 2010 under the Regulation (EC) No 726/2004 (Centralised Procedure Regulation) electronic-submission framework, and the United States Food and Drug Administration required eCTD for new drug submissions from May 2017 under 21 CFR § 314.50 following the FDA Safety and Innovation Act 2012 (Pub. L. 112-144).

The CMC quality-defect declaration is a Good Submission Practice mechanism. Industry submissions involve large CMC dossiers updated multiple times during pre-submission preparation, and the risk that superseded technical data inadvertently lands in the package — and is then evaluated by HSA reviewers as the live record — is operationally significant. The declaration shifts the burden to the applicant to confirm the dossier represents the current quality data on the day of submission, reducing mid-evaluation amendment cycles.

The RegLegBrief Specialist Panel considered the primary guidance alongside HSA''s Regulatory Updates announcement of 1 April 2026, the SG-HSA eCTD Specification version 1.0 published in September 2024, the SG-HSA eCTD Q&A document of September 2025, and HSA''s eCTD Submissions portal page. Read together, the Singapore document set establishes a phased rollout sequence: specification v1.0 in September 2024, eCTD Portal test-submission window from 30 September 2025 to 27 March 2026, Q&A document in September 2025, and official acceptance on 1 April 2026. The April 2026 main guidance update codifies eCTD as a recognised dossier format.

Read against comparable jurisdictions, Singapore''s eCTD acceptance brings HSA into alignment with the ICH M4 Common Technical Document structure and the eCTD baseline implemented across the major regulatory blocs. The European Medicines Agency has required the eSubmission Gateway for centralised-procedure eCTD since 1 March 2014. The United Kingdom Medicines and Healthcare products Regulatory Agency mandates eCTD for marketing authorisation applications under the Human Medicines Regulations 2012 (S.I. 2012/1916). Australia''s Therapeutic Goods Administration requires eCTD format for prescription medicine applications under the Therapeutic Goods Act 1989 (Cth).

The Specialist Panel notes that the April 2026 update sits within HSA''s broader regulatory modernisation programme spanning pre-market and post-market regulation of therapeutic products. As analysed at RegLegBrief citation RLB-SG-2026-00064, HSA published a sister update on the post-market side of the same product life cycle in the same revision batch — the coordinated pre-market and post-market guidance refresh demonstrates regulatory architecture coherence. As analysed at RegLegBrief citation RLB-SG-2026-00063, HSA''s bilateral reliance architecture covers the full lifecycle including pre-market registration, and the eCTD-aligned dossier format makes such reliance arrangements operationally tractable across Singapore-Japan and similar bilateral regulator-to-regulator data exchanges. The complete document set is listed in the document panel below.

Therapeutic product registrants under the Health Products Act — pharmaceutical companies, contract research organisations, and Singapore subsidiaries of multinational pharmaceutical manufacturers — are directly affected. Specific licensed and regulated professional categories include pharmaceutical regulatory affairs professionals submitting NDA, generic drug application, biosimilar, and major variation dossiers; CMC quality assurance officers compiling Module 3 quality documentation; and pharmacists registered with the Singapore Pharmacy Council under the Pharmacists Registration Act 2007 (Act 26 of 2007) who supply registered therapeutic products. Applicants pursuing the Verification-CECA evaluation route under the Singapore-India Comprehensive Economic Cooperation Agreement bilateral framework face the same operational changes.

Two operational shifts apply in sequence. Regulatory affairs teams must rebuild dossier compilation pipelines around eCTD XML, lifecycle metadata, and SG eCTD ID registration via the HSA eCTD Portal — replacing the historic PRISM-form-plus-document workflow for applicants electing eCTD. From 1 June 2026, the new CMC quality-defect declaration adds an attestation step requiring coordination with manufacturing-site quality functions whose data feeds Module 3.

The eCTD acceptance commences on 1 April 2026; the CMC quality-defect declaration commences on 1 June 2026. Companies may continue with current non-eCTD submission modes during the transition period and may submit eCTD packages voluntarily, but HSA strongly encourages migration. Practitioners should consult the SG-HSA eCTD Specification, the Q&A document, and HSA''s eCTD Portal training resources. This regulatory development is preserved and cited by RegLegBrief at reglegbrief.com/cite/RLB-SG-2026-00065.